Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years
Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, Quintana LM, Tamimi RM, Hankinson SE
Cancer research · 38 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (P01 CA087969); National Cancer Institute (UM1 CA186107); National Cancer Institute (R01-CA49449); National Cancer Institute (R01‐CA049449); National Cancer Institute (P01 CA87969 and UM1 CA186107); National Cancer Institute (U01 CA049449)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2016-08-17 · Cancer Res · vol. 76 · número 18 · págs. 5423–5430
- Editorial
- American Association for Cancer Research
- Citado
- 45 citas · más que el 96% de estudios similares · 4.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 43 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Thyroid Disorders and Treatments · Cancer Risks and Factors
- Palabras clave
- Calcitriol receptor, Vitamin D and neurology, Medicine, Breast cancer, Internal medicine, Relative risk, Confidence interval, Gastroenterology, Tissue microarray, Endocrinology, Cancer, Oncology
- MeSH
- humans, breast neoplasms, vitamin d, retinoid x receptors, receptors, calcitriol, radioimmunoassay, oligonucleotide array sequence analysis, tissue array analysis, immunohistochemistry, logistic models, risk factors, case-control studies, follow-up studies, prospective studies, adult, aged, middle aged, female
8 autores
- A. Heather Eliassen🇺🇸 · autor de correspondenciaBrigham and Women's Hospital; Harvard University
- Erica T. Warner🇺🇸Massachusetts General Hospital
- BERNARD A. ROSNER🇺🇸Brigham and Women's Hospital; Harvard University; Cancer Research And Biostatistics
- Laura C. Collins🇺🇸Beth Israel Deaconess Medical Center
- Andrew H. Beck🇺🇸Beth Israel Deaconess Medical Center
- Liza M. Quintana🇺🇸Beth Israel Deaconess Medical Center
- Rulla M. Tamimi🇺🇸Brigham and Women's Hospital; Harvard University
- Susan E. Hankinson🇺🇸Brigham and Women's Hospital; Harvard University; University of Massachusetts Amherst
Resumen
El texto original del estudio, en el idioma en que se publicó.
Experimental evidence supports a protective role of 25-hydroxyvitamin D [25(OH)D] in breast carcinogenesis, but epidemiologic evidence is inconsistent. Whether plasma 25(OH)D interacts with breast tumor expression of vitamin D receptor (VDR) and retinoid X receptor-α (RXR) has not been investigated. We conducted a nested case-control study in the Nurses' Health Study, with 1,506 invasive breast cancer cases diagnosed after blood donation in 1989-1990, 417 of whom donated a second sample in 2000-2002. VDR and RXR expression were assessed by immunohistochemical staining of tumor microarrays (n = 669 cases). Multivariate relative risks (RR) and 95% confidence intervals (CI) were calculated using conditional logistic regression. Plasma 25(OH)D levels were not associated with breast cancer risk overall [top (≥32.7 ng/mL) vs. bottom (<17.2 ng/mL) quintile RR = 0.87; 95% CI, 0.67-1.13; P trend = 0.21]. 25(OH)D measured in summer (May-October) was significantly inversely associated with risk (top vs. bottom quintile RR = 0.66; 95% CI, 0.46-0.94; P trend = 0.01); winter levels (November-April) were not (RR = 1.10; 95% CI, 0.75-1.60; P trend = 0.64; P interaction = 0.03). 25(OH)D levels were inversely associated with risk of tumors with high expression of stromal nuclear VDR [≥30 ng/mL vs. <30 ng/mL RR (95% CI): VDR ≥ median = 0.67 (0.48-0.93); VDR < median = 0.98 (0.72-1.35), P heterogeneity = 0.12] and significantly stronger for summer measures (P heterogeneity = 0.01). Associations were not significantly different by RXR expression. No overall association was observed between plasma 25(OH)D and breast cancer risk. However, our results suggest women with high, compared with low, plasma 25(OH)D levels in the summer have a reduced breast cancer risk, and plasma 25(OH)D may be inversely associated with risk of tumors expressing high levels of VDR. Cancer Res; 76(18); 5423-30. ©2016 AACR.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.